Vertex Pharmaceuticals (VRTX.US): Phase IIb data increases probability of success for Inaxaplin

J.P. Morgan North America Equity Research analyst Jessica Fye published a report on September 22, 2026, covering Vertex Pharmaceuticals (VRTX.US). The report notes that Phase IIb data increased the probability of success for Inaxaplin. J.P. Morgan maintains an Overweight rating on the stock with a price target of $560 (as of September 11, 2026); the rating history shows the stock has long carried an Overweight rating, with the price target progressively raised from $390 to $560. The report also discloses that J.P. Morgan Securities is acting as financial advisor to Crinetics Pharmaceuticals in connection with its acquisition by Vertex Pharmaceuticals (announced July 6, 2026), a transaction subject to customary closing conditions including regulatory approvals and Crinetics shareholder approval.